According to the worldwide study held on Milvexian, it is effective against the patient with knee arthroplasty. It is effective against the prevention of venous thromboembolism. Researchers found that Milvexian is unique, and works by targeting the factor Xla, a clotting factor or enzyme that causes dangerous thrombosis.

The researchers held a study on 1,242 patients from 18 countries who were about to undergo knee replacement surgery. They were enrolled between June 2019 to February. They compared Milvexian with enoxaparin for the prevention of blood clots in these patients.

In this study, they found that a daily dose of 100mg or more of Milvexian resulted in better blood clot protection, when compared to enoxaparin there was no increase in bleeding. Later, Milvexian was evaluated in daily doses from 25 to 400mg and there was no bleeding during these doses.

According to a senior professor in the field of medicine and biochemistry, “The major side effect of current oral anti-clotting drugs is bleeding, and the fear of bleeding leads to their underuse. This sets the need for safer oral anticoagulants and that is where Milvexian comes in.” 

According to the research, blood clots are responsible for 1 in 4 deaths worldwide. It is also the cause of an underlying disease known as heart attack, stroke, pulmonary embolism, and deep vein thrombosis. Most of these conditions require lifelong anticoagulant treatment. 

Anticoagulants are also known as blood thinners and they are the main foundation for the treatment and prevention of clots in veins and arteries. Therefore, oral anticoagulants like Milvexian are in high demand as it reduces the burden of lifelong conditions.

This study has been focused mainly on knee replacement surgery patients because they are at a higher risk of postoperative blood clots. These types of blood clots can be easily found in X-rays and venograms of the legs. Hence, these patients have been involved in new anticoagulants study.  This patient population provides an ideal testing ground for new anticoagulants because effective and safe doses can be identified.

Milvexian is the first one among the several investigations of oral factor XIa inhibitors and the result of the study is still in process and most probably it will be released by next year.